Wallace and Chen described potent and selective specific antagonists of HIF‐2α in ccRCC, PT 2385, and PT 2399, respectively, in the same year, and clinical trials are underway [85–87]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.